ABSTRACT. Seventy-nine HIV-1 infected patients were studied in three groups: Group G 1 -11 patients with no antiretroviral therapy; G 2 -40 patients undergoing antiretroviral therapy, 33 with only two nucleoside reverse transcriptase inhibitors (NRTI), and seven with two NRTI and one protease inhibitor (PI), all with viral load (VL) equal or higher than 80 copies of plasma RNA/ml; Group G 3 -28 patients, 23 on highly active antiretroviral therapy (HAART), 18 with two NRTI and one PI, and five with two NRTI and one non-nucleoside reverse transcriptase inhibitor (NNRTI), the remaining five with combination of two NRTI.
between all groups (H=6.071; p>0.10; G 1 =G 2 =G 3 =G c ). In absolute values however, G 3 showed slightly lower TNF-α, IL-4, and IL-10, and higher INF-γ and IL-2, to G 1 and G 2 . This suggests a better performance in G 3 patients, especially in IL-2 behavior. For cytokine profile, the three groups showed mature Th0 subset. In G 1 72.73% were mature Th0, and 27.27% Th2; G 2, 72.50% mature Th0, and 27.50% Th2; and G 3 , 89.29% mature Th0, and 10.71% Th2.
There was no statistical difference between groups (χ 2 2 =3.014; p>0.10; G 1 =G 2 =G 3 ). Statistical difference was seen between G 2 and G 3 for antiretroviral regimes used (χ 2 1 =27.932; p<0.001; G 3 >G 2 ); HAART with PI predominated in G 3 , suggesting that it was responsible for this better performance. Linear correlation between pairs of variables was made with patient groups only, excluding controls. This was made separately for G 1 The progression of HIV-1 infection would appear to depend on the immunogenetics of the host (34) and in the other hand with virologic factors (17) .
In view of this, progression markers of HIV-1 infection are important for HAART follow-up.
Several studies have indicated the importance of CD4 + T/mm³ lymphocyte count (22, 28) , the determination of viral load (VL) (20, 21, 22) ; these being markers of the natural history of HIV-1 infection, biological activity, and therapeutic efficacy. However, they are quantitative indices and do not always show immune function compromise.
Clerici and Shearer, in 1993 (5), reported Th-1/Th-2 polarization to associate the progression of AIDS with loss of IL-2 and INF-γ production, together with increased IL-4 and IL-10.
They also mentioned that seronegative individuals exposed to HIV-1 showed strong Th-1 response. Other authors have highlighted the Th-1/Th-2 paradigm (30), the transcriptional regulation of Th-1/Th-2 polarization (29), and the relationship of these profiles with infectious diseases (14) .
The most important fact in the natural history of HIV-1 infection is the infected organism's incapacity to sustain the vigorous immune response expressed immediately after infection and during the primary infection phase, with or without acute disease; this is characterized by the proliferation of specific cytotoxic T lymphocytes and increased levels of complement (C') binding antibodies. of the assymptomatic or oligosymptomatic phase that can last years and be followed by AIDS, which results from immunosuppression, establishes itself, and is characterized by the decline of CD4 + T lymphocytes to below 200/mm³ and increased viremia (25) .
The HAART has produced changes in patient behavior, resulting from the viral population dynamics response to this therapy, many of which change to undetectable viral load (12 (8) . When VL reduction is 1.0 log, this increase is only 5% (8).
The biggest problem for those treating HIV-1/AIDS patients is obtaining information on the functional state of immune response; they need other markers to see if there is immunological recovery or not (13, 33) .
Cytokine behavior has shown that inhibition of viral replication resulting from ARV can reverse IL-2 and INF-γ suppression, at the same time that there is a reduction in IL-4 and IL-10 production (13, 31, 36 
PATIENTS AND METHODS

Patients
Considered parameters Clinical
All 79 HIV-1 infected individuals (G 1 , G 2 , and G 3 ) were submitted to full clinical observation including associated opportunistic diseases at time of blood collection for cytokine detection.
In the 68 treated patients (G 2 and G 3 ), the specific ARV regimens were also considered: double -two NRTI; or HAART -two NRTI plus one PI, or one NNRTI. 
HIV-1 plasma viral load determination
Blood (10ml) from each infected individual was tested for HIV-1 plasma VL by the NucliSens HIV-T (Bio Merieux) test, characterized by amplification of nucleic acids based on NASBA technology (2, 16, 32) .
CD4 + T CD8 + T/mm³ lymphocyte counts
Quantitative determination of T lymphocyte subpopulation with CD4 + and CD8 + markers was performed using flow cytometry and Coulter Monoclonal Reagents. We collected 3ml of venous blood from each patient (G 1 , G 2 , and G 3 ) using a Vacutainer system, in a tube with EDTA anticoagulant (2mg/ml blood). The sample was kept at room temperature, processed 4 hours after collection, and submitted to Coulter T-890 automatic counter. 
Serum cytokine determination
We collected 8ml of blood, in dry tube, from the 79 HIV-1 (G 1 , G 2 , and G 3 ) and the 20 normal (G c ) individuals; serum was separated, aliquoted, and stored at -70°C. TNF-α, INF-γ, IL-2, IL-4, and IL-10 cytokines were determined by ELISA, using Quantkine IL-2E Kits (R&D Systems, Mineapolis, MN). Initially 96-well microplates were sensitized with determined anti-cytokine monoclonal antibody (TNF-α, INF-γ, IL-2, IL-4, and IL-10). Next, 200µlof test, positive control, and negative control sera were added (dilution 1:2); they were incubated at 37°C for periods ranging from 30 to 60 minutes depending on cytokine. Four washes were performed with detergent solution containing 2-chloroacetamide (0.1%). This was repeated until the phase preceding substrate addition. Later, biotin marked plates received streptovidine-peroxidase. After incubation, a substrate of hydrogen peroxide (0.02%) and tetramethylbenzine (2%) was added. Reaction was interrupted at room temperature with 2N sulfuric acid. Results were evaluated by reading optical density (OD) in a Titertek Multiscan automatic ELISA reader at 450nm. Serum cytokine concentrations were calculated from a standard curve (19, 23) .
In vitro cytokine determination
We collected 15ml of blood in dry tube with 0.1 heparin from five randomly chosen G c individuals, to obtain mononuclear cells by separation in Ficoll-Hypaque gradient (3). The lymphocyte and monocyte rich ring was initially washed in ice-cold EDTA-PBS solution for five minutes at 200g, and then with RPMI culture medium for another five minutes at 200g.
After this, the cell suspension was resuspended in 1640 RPMI (Gibco Laboratories, Grand Island, NY) supplemented with 2mM L-glutamine (Sigma Chemical Co. USA), 40µg/ml gentamicine, and 10% deactivated human AB serum (complete cell culture medium: CCCM); mononuclear cell identification and assessment of viability were made by count in 5% Turk and monocyte isolation by neutral red (50µlaliquots of cell suspension were incubated at 37°C for 10 minutes with 0.45ml staining solution at 0.02%). Next, the cell suspension was distributed in 96-well plates at different concentrations according to experiment. For monocyte isolation, after 1 hour incubation at 37°C in 5% CO 2 tension, the non-adherent cells were eliminated by washing the plates with RPMI culture medium. Total mononuclear cells (2x10 6 /ml) were incubated at 37°C in 5% CO 2 centrifuged at 2000 rpm; aliquots were then stored at -70°C until used for cytokine determination. This was performed by ELISA, using commercial kits from R & D Systems as described for serum cytokines.
Statistical analysis
Comparison between groups G 1 , G 2 , G 3 , and G c according to serum cytokine determination was made by analysis of variance (ANOVA) for entirely randomized experiments (ERE), and by non-parametric Kruskal-Wallis test (35) . Groups G 1 , G 2 , and G 3 were also compared according to CD4 + T and CD8 + T/mm 3 lymphocytes, and with VL determination by ANOVA for ERE, and the non-parametric Kruskal-Wallis test (35) . Linear comparison between pairs of studied variables was made by Spearman's coefficient (35) . Serum cytokine profiles were We were unable to measure IL-4 and IL-10 levels (equal to zero) in some control group (G c ) individuals. There was no statistical difference between G 1 , G 2 , and G 3 for INF- γ, IL-4, IL-10, and TNF-α. All were statistically different to G c . There was no statistical difference in IL-2 between all groups, including G c . With regard to cytokine profiles, no group (G 1 , G 2 , and G 3 ) showed subset Th1 profile (31); all three showed mature Th0 subset (31) . The distribution of serum cytokine profiles in the 79 HIV-1 infected patients (G 1 , G 2, and G 3 ) showed that none had Th1, or naive Th0 subsets (31) . Therefore from the 11 G 1 patients, eight (72.73%) were mature Th0 subset, and the other three (27.27%) Th2; in G 2 , 29 (72.50%) were mature Th0 subset and 11 (27. with two NRTI and undetectable VL for at least the last 6 months.
RESULTS
Normal values of serum cytokines
Definition of cytokine serum profiles in the study groups
Antiretroviral therapy
From the 68 under treatment, 40 were G 2 , of which 33 (82.5%) received two NRTI and the other seven (17.5%) two NRTI and one PI; from the 28 G 3 , 18 (64.28%) received two NRTI and one PI, and the other five (35.72%) two NRTI and one NNRTI. There was statistical difference between G 2 and G 3 (χ Table 2 
Linear Correlation between pairs of variables
DISCUSSION
The destruction of CD4 + T lymphocytes has generally been accepted as a direct consequence of the immune-pathogenesis in HIV-1 infection. Also that viruses indirectly control noninfected CD4 + cell mechanisms driving them to apoptosis and destroying them after antigenic activation (11) . Many authors have found a reduction in IL-2, IL-12, and INF-γ, and an increase in IL-4 and IL-10 production during the evolution of HIV-1 infection (1, 6, 15 authors have reported that combined HAART causes a reduction in viral replication, reverses IL-2 and INF-γ suppression, and decreases IL-4 and IL-10 production (4, 11, 12, 13, 19, 31) . However, the increase in CD4 + , as a result of the antiretroviral treatment, is complex. It is in part due to the blood trafficking these cells, which were sequestered in the lymphatic compartment (24) , also to the increased production rate of circulating lymphocytes resulting from the expansion of peripheral T cells (10) , apoptosis suppression, and new T cell production (9) . To help interpret patient immune response during antiretroviral therapy, mainly HAART, and verify if immunity regeneration is occurring, other progression markers should be used with CD4 + cell and VL count. Haase (12) reported that immunity regeneration by treatment is slow, variable, and partial. In fact there is not always an increase in CD4 + cells, and when there is, it may be due to recirculation of cells retained in the lymphatic system and not naive or memory cells. Also when VL becomes undetectable and remains so in later controls, it cannot be used to evaluate immunity recovery. This is a cross-sectional study with HIV-1 patients in three groups according to antiretroviral therapy: one group without treatment, and the other two with treatment; VL in one group being equal or higher than 80 copies, and in the other undetectable. A fourth group of normal uninfected individuals were used as controls to establish normal serum values, define profiles, and types of cytokines (31) . In the HIV-1 groups, we also considered CD4 + T and CD8 + T lymphocyte count, and
VL.
There is no international normal standard for serum cytokines; they are produced by activated T cells. It is possible to determine cytokine levels in activated cell supernatant or serum using ELISA as in this study (18, 19, 31) . These methods measure the quantity of cytokines produced by T cell population, as it is impossible to estimate the quantity of cells that produced them (18) . In this study, we compared serum and in vitro cytokines collected from five randomly selected control group individuals. There was no significant difference in "1", "mature 0", and "2" profile cytokine definer values (INF-γ, IL-2, IL-4, and IL-10). There was significant difference only for TNF-α , which is not a profile definer. The levels of profile definer cytokines were therefore equivalent by both methods in this study.
CD4
+ and CD8 + cell count was higher in the non-treated group (G 1 ) than the treated groups (G 2 and G 3 ), which were equivalent independent of VL detection and without differences in behavior. These observations do not invalidate the efficacy of antiretroviral therapy but in a way agree with Haase (12) that immunity regeneration under this treatment is slow, variable, and partial, especially when naive cells (CD45RA) and memory cells (CD45RO) are considered. Gougeon et al (11) agreed that immune system restoration is quantitatively and qualitatively partial despite having shown an increase in these cell populations together with a VL however displayed different behavior between groups with a drop of 0.5 log from G 1 to G 2 and 4.0 log from G 2 to G 3 ; it was used for group classification, especially as a surrogate marker for G 2 and G 3 . In this study, when analyzed, it had less meaning despite agreeing with Haase (12) and Carcelain et al (4) .
Several studies have reported the effect of HAART in AIDS patient's immunity reconstitution (13, 31, 33) ; treatment significantly inhibited viral replication and the consequent reduction of IL-2 suppression and INF-γ production, while promoting IL-4 and IL-10 decrease. In this study, we observed that TNF-α, INF-γ, IL-4, and IL-10 were statistically higher than in the control group, but there was no statistical difference between all HIV-1 groups. IL-2 was the only cytokine that was not statistically different between all groups including controls. In absolute values, IL-2 increased with the lowest values in non-treated patients (G 1 ). It was also lower in treated detectable VL (G 2 ) patients than controls. The highest value was in undetectable VL (G 3 ) patients; its absolute value was higher than the control group median and, when considered in absolute values, showed a behavior suggesting immunity reconstitution.
According to the Spellberg and Edwards-Jr (31) definition of cytokine profile behavior, and considering median cytokine values in each group, all patient groups (G 1 , G 2 , and G 3 ) had mature Th0 subset. On the other hand, considering each patient from each group, none of them showed Th1 or naive Th0 subset profile. This latter is defined by IL-2 production. In contrast, the highest proportion in each group was mature Th0, and the lowest Th2. Despite no statistical difference between groups, the group with the lowest proportion of Th2 was treatment with undetectable VL; this is relevant as could be the result of the antiretroviral treatment, mainly HAART, administered to this group (7, 27, 31) .
In relation to ARV treatment in the study groups, most G 3 patients received triple regimen associated with two RITN and one PI (HAART). The patients in this group performed best with undetectable VL, higher increase in IL-2, which was higher than controls; and lower Th2. These results are in agreement with several authors (4, 8, 11, 12, 13, 24, 31, 33 Correlation of pairs of variables using the detectable viral load groups, G 1 (infected, nontreated) and G 2 (infected, treated), against these two groups plus G 3 (undetectable VL)
showed IL-2 with the most correlations. IL-2 correlated positively with INF-γ , the definer of Th1 subset (5, 31) , and with CD4 + T, an immunity recuperation surrogate marker (12);
negatively with VL, TNF-α, IL-4, and IL-10. VL is a surrogate marker of disease progress (20, 21) . According to Gougeon et al (11) , the T cells responsible for producing TNF-α are more sensitive for inducing apoptosis than those responsible for IL-2. Apoptosis is the main CD4 + T reduction mechanism in HIV-1 infection (11). IL-4 and IL-10 are definers of Th2 subset (31) . The positive and negative correlations of IL-2 to the above variables make it an important marker of immunity recuperation in HIV-1 infected patients under HAART. In this sense, IL-2 serum determination may be useful in follow-up of these patients together with VL determination and CD4 + T/mm 3 cell count.
